|
|
||||||||
Clinical Investigation |
1 Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 2 Department of Radiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; and 3 Department of Surgery A, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Correspondence: For correspondence or reprints contact: Ur Metser, MD, Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizman St., Tel-Aviv, 64239 Israel. E-mail: umetser{at}tasmc.health.gov.il
Our purpose was to evaluate the performance of 18F-FDG PET/CT, using data from both the PET and the unenhanced CT portions of the study, in characterizing adrenal masses in oncology patients. Methods: One hundred seventy-five adrenal masses in 150 patients referred for 18F-FDG PET/CT were assessed. Final diagnosis was based on histology (n = 6), imaging follow-up (n = 118) of 629 mo (mean, 14 mo), or morphologic imaging criteria (n = 51). Each adrenal mass was characterized by its size; its attenuation on CT, expressed by Hounsfield units (HU); and the intensity of 18F-FDG uptake, expressed as standardized uptake value (SUV). Receiver operating characteristic curves were drawn to determine the optimal cutoff values of HU and SUV that would best discriminate between benign and malignant masses. Results: When malignant lesions were compared with adenomas, PET data alone using an SUV cutoff of 3.1 yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 98.5%, 92%, 89.3%, 98.9%, respectively. For combined PET/CT data, the sensitivity, specificity, positive predictive value, and negative predictive value were 100%, 98%, 97%, 100%, respectively. Specificity was significantly higher for PET/CT (P < 0.01). Fifty-one of the 175 masses were 1.5 cm or less in diameter. When a cutoff SUV of 3.1 was used for this group, 18F-FDG PET/CT correctly classified all lesions. Conclusion: 18F-FDG PET/CT improves the performance of 18F-FDG PET alone in discriminating benign from malignant adrenal lesions in oncology patients.
Key Words: adrenal mass adenoma 18F-FDG PET/CT
This article has been cited by other articles:
![]() |
A. B. Elaini, S. K. Shetty, V. M. Chapman, D. V. Sahani, G. W. Boland, A. T. Sweeney, M. M. Maher, J. T. Slattery, P. R. Mueller, and M. A. Blake Improved Detection and Characterization of Adrenal Disease with PET-CT RadioGraphics, May 1, 2007; 27(3): 755 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Mitchell and F. E. Nwariaku Adrenal Masses in the Cancer Patient: Surveillance or Excision Oncologist, February 1, 2007; 12(2): 168 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chong, K. S. Lee, H. Y. Kim, Y. K. Kim, B.-T. Kim, M. J. Chung, C. A Yi, and G. Y. Kwon Integrated PET-CT for the Characterization of Adrenal Gland Lesions in Cancer Patients: Diagnostic Efficacy and Interpretation Pitfalls RadioGraphics, November 1, 2006; 26(6): 1811 - 1824. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Intenzo, K. S. Lee, and B.-T. Kim Invited Commentary * Authors' Response RadioGraphics, November 1, 2006; 26(6): 1824 - 1826. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |